Easily detect your biological nanoparticles A spin-off from the Institut d'Optique Graduate School, Université Paris-Saclay, UNVEIL is a deeptech start-up that facilitates the development and production of biologics (drugs derived from living organisms, such as messenger RNA vaccines, as opposed to chemical ones). These biologics (gene therapy, RNA vaccines, etc.) are transported to the target site in the human body by nanometric vectors (viruses or lipid nanoparticles). R&D and production of these biomedicines is hampered by the lack of effective technology to measure vector loading. UNVEIL has developped an optical, label-free instrument capable of quickly and easily measuring nanovector loading …

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Antibody Targeted Biologics atbtherapeutics is a pioneering biopharmaceutical company building a new line of attack against cancer. atbtherapeutics has developed the atbody; a game-changer biologic format designed to broaden the therapeutic window of antibody-based therapies. Only our proprietary and versatile plant-based atbiofarm technology enables single-step manufacturing of our novel class of therapeutic atbodies. The resulting therapeutics offer a novel mechanism of action, avoiding major cancer cell resistance, and provide a promising, life-changing therapy for hard-to-treat and refractory cancer.

100 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering next-generation antibody therapies with AI and computational protein design Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines. Archon …

83 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Precision Vaccines Company Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity. Drug development, Cellular immunity, and Platform technology

260 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Discovery of novel immune checkpoint inhibitors for cancer immunotherapy OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered …

209 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Streamlining nanoparticle formulation to release the full power of RNA-LNPs and nanomedicines. InsideTx streamlines RNA-LNP formulation from screening to manufacturing. Founded at the intersection of microfluidics and biotechnology, we build formulation platforms that cover the full RNA-LNP & nanomedicine development pipeline — so researchers can focus on the science, not the process. TAMARA is our all-in-one R&D platform for nanoparticle formulation. It handles everything from early screening to preclinical in-vivo studies in a single instrument (0.2–30 mL), with zero formulation losses, reusable microfluidic chips, and two mixing geometries on one reversible chip. As one of our users put it: "I'm …

85 similar entities Type: Startup Activities: manufacturing nanotech deeptech biotech Technologies: Synthetic Biology SaaS

Pioneering Patient-led Antibody Therapeutics Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease. Antibody Therapies, Immunology, and Neuro-dengeneration

83 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Combining human and machine intelligence to discover the next generation of therapeutic antibodies. LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVATM is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles. Medical, Health, and DNA Libraries

140 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: A.I. Robotics Synthetic Biology A.I. - Machine Learning

new tools for better research #newtoolsforbetterresearch Part of Proteintech Group. ChromoTek pioneered the development and commercialization of alpaca Nanobodies. As a market and product leader for high quality and reliable Nanobody-based reagents, we assist scientists’ research world-wide. In addition, ChromoTek is a trusted service provider of custom-made Nanobodies for the pharmaceutical industry. Founded in 2008 ChromoTek has offices in Martinsried, Germany, and Hauppauge, NY. In contrast to traditional antibodies Nanobodies consist of only one single polypeptide chain; they are 15 kDa and the smallest antibodies known. ChromoTek GmbH, Affinity purification, Immunoprecipitation, Co-IP, Mass spectrometry, Ligand capture, Protein-protein interaction, GFP-Trap, Fluorescent …

61 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Laigo's SureTAC platform enables rapid therapy development for removal of disease-driving membrane proteins #laigobio Laigo's proprietary SureTAC platform empowers us to rapidly develop first-in-class dual targeted therapies that eliminate disease-driving membrane targets using straightforward bispecific antibody technology. We are committed to exploring an ever-evolving universe of new targets, including those currently considered undruggable, and we are open to strategic partnerships to make meaningful advancements in treating diseases that lack effective treatment options today. Laigo Bio is where innovation meets life-changing solutions, forging a path toward a healthier tomorrow. #TPD #Protac #membraneprotein #bispecificantibody #antibody #proteindegradation #roteindegrader #LaigoBio #oncology #neurobiology #immunology #SureTACs

146 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class ADCs tailored to attack advanced cancer Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer Blue Bees Therapeutics is a biotechnology company founded in March 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay. This technology allows to generate antibodies stimulating the anti-tumor immune response via a double cell receptor targeting coupled with heparan sulphate proteoglycans (HSPG). Immunothérapie, Immuno-oncologie, pharma, Biotech, Immunologie, Oncologie, Cancer, Médicament, and Drug

228 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Proteins Structures Got Easier With Crystallophores Emerged from academic research, POLYVALAN (IBS & ENS Lyon Spin-off company) is a young innovative company founded in December 2016 dedicated to structural biology. POLYVALAN competitive edge is its unique chemical approach allowing significant gain of effectiveness, time and/or precision for protein structure determination that allows an optimal use of the existing large equipments. structural biology, protein crystallization, crystallization screening, nucleating agent, phasing agent, crystallophore, structure determination, X-ray crystallography, and drug design

69 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Built around safe-by-design concept, Adjuvatis is committed for innovative formulations to improve pharmaceuticals Adjuvatis, a French startup in biotechnology, develops innovative safe-by-design delivery systems to help laboratories and pharmaceutical companies in vaccine formulation as adjuvants and in drug delivery as vectors for oncology, dermatology, infections, etc. Our first technology, called i-Particles®, is based on 200 nm-diameter particles composed of poly-lactic acid only (any surfactant and solvents) for formulation of hydrophobic molecules in the particle core and surface functionalization of peptides. Our second technology, i-LipoP®, consists in i-Particles® covered by lipidic bilayers at their surface for vectorization of nucleic acids and …

100 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nanomaterials as Nanomedicines: let's play collective! SUPERBRANCHE : Nanomedicine as a breakthrough to treat cancer We bring answers to the following issue: intratumoral injection of nanomaterials implying both accessibility and detection of the tumor beforehand. We position ourselves as a producer dedicated to the synthesis of architectured nanomaterials as simple as possible and of controlled size. Our modular technology platform presents both therapeutic and diagnosis applications. It consists in a magnetic nanoparticle coated by a tailor made branched architecture. Thanks to their optimized shape and stability, our compounds are well tolerated and can be administered intravenously, thus helping to the …

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

OneHealth/AI DeepTech discovering patentable mixes of natural ingredients preserving health and optimizing bioprecesses Alphanosos, a Green One-Health DeepTech company, uses its own Artificial Intelligence algorithms to discover, develop and market active ingredients and products based on blends of extracts from non-pharmaceutical ingredients, in particular edible plants. These active mixtures, some of which are already patented in 15 countries for their antimicrobial activities, are intended for the animal hygiene, dermocosmetics, food preservation and cosmetics sectors, bioprocess optimization and in the longer term, for functional foods and disease treatments. The company began its Research and Development (R&D) activities in mid-2015 and is …

224 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I.

NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors NanoMedSyn was born from the fundamental research of its biologist and chemist founders who discovered a breakthrough technology for drug delivery to the lysosomal cell compartment leading to potentiation of therapeutics. This technology, validated at the preclinical level, has a wide range of applications in the fields of oncology, immunity, inflammation or metabolism. NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA. The main application is the engineering of recombinant proteins like antibodies or enzymes for …

175 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We produce customised chemical proteins to help our bio-pharms partners to accelerate their projects. 🧪 X’PROCHEM is a biotech company who invented an advanced and proprietary ligation technology. We help our bio-pharma partners design and create therapeutic, vaccine and diagnostic proteins. Unlike recombinant fermentation we can produce proteins containing up to 400 amino acids, without isoforms, endotoxins, or biological contaminants. We co develop solutions with our partners to understand the real needs within the context. By working closely, we can adapt to changing needs and circumstances. protein, purification, synthesis, protein production, peptide synthesis, and life sciences

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's dual mechanism of action allows it to act as a 'primer' to re-engage the patient's immune system while at the same time targeting cancer cells directly. OBT’s proprietary OGAP® target discovery platform …

134 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advanced Nanotechnologies A nanobiotechnology and smart polymers company. The company is committed to products for several engineering the biomedical sectors, with an emphasis on tissue engineering, drug delivery and functionalized electrospun nanofibers. Nanofaber Srl is the exclusive distributor on the Italian soil of Bioinicia Fluidnatek Slu, leader company in Europe regarding the electrospinning equipment and services. Through its high-specialized division, Nanofaber can offer to its clients premium equipment, services and commercial/technical assistance on the electrospinning and electrospraying technology. nanofibers, SERS, oncoproteins, and nanomechanics

58 similar entities Type: Startup Activities: nanotech deeptech Technologies: Synthetic Biology

Accelerating antibody discovery with AI bioinformatics solutions for the pharma industry NaturalAntibody develops bioinformatics solutions to facilitate the process of engineering antibody-based therapeutics. The company collects, integrates, and repurposes antibody data points across public and proprietary repositories to learn about antibody structure, function, and diversity. Its solutions support researchers in making the process of designing therapeutic antibodies and drug discovery faster and safer.

62 similar entities Type: Startup Activities: deeptech it services biotech Technologies: A.I. Synthetic Biology

Chemical tools for bioconjugaison & biodrugs McSAF is a Deeptech company specialized in Bio-Organic & Bio-Conjugates Chemistry, developing innovative technologies for improved targeted therapies. Its core expertise covers Therapeutic Peptides and Proteins, Antibodies, and Drug Conjugates. The team has a strong background in synthetic selective chemistry, and a real expertise in bioconjugation, including specific designs of Antibody Drug Conjugates (ADCs) with own proprietary coupling technology. Plus, the company has now a pipeline of three products in oncology incorporating McSAF Inside technology with the ambition to bring new biodrugs on the market solving unmet medical needs. Bioconjugation, Biopharmaceuticals, Antibody Drug Conjugates, …

135 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

AlpalifeBio, specialized in VHH Discovery solutions. Stay connected to explore the limitless potential of SdAb with us! Alpalifebio is a biotechnology company in China founded by scientists with strong background in antibody production, G protein coupled receptors (GPCRs) drug discovery. Now we exclusively engage in development and production of customized well-performed Alpaca Nanobodies (Single-domain antibodies or VHHs) in high-quality for cytoplasmic proteins, membrane proteins (especially GPCRs) and bio-medical research. AlpaLifeBio has been working with multiple top pharmaceutical companies in China, also built a good relationship with global clients, trying to provide every client the best service, quality and price. AlpaLife …

85 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Building a pipeline of immuno-therapies to fight against cancer and multiresistant pathogens ALPIONER Therapeutics is a biotech company developing new generation of immunotherapies against cancer and multi-resistant pathogens. Its aT3-plaform is leveraging a bacterial secretion system to inject high quantity of peptides or functional proteins, into the cytosol of the host cell. ALP-102 is a first-in-class vaccine candidate targeting Pa infections while ALP-201-neo is neoantigen-based personnalized cancer vaccine.

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building the Future of Precision Medicines through V-Body, RNA and In Vivo Cell Engineering Platforms. At Valerio Therapeutics, we are pioneering a new generation of precision therapies to tackle complex and underserved diseases. Our proprietary V-Body platform is based on two fully synthetic single-domain antibody (sdAb) libraries, derived from a human VH and a fully humanized VHH. Engineered for optimal performance, this ultra-small sdAb platform (~15 kDa) surpasses the limitations of current treatments by enabling deep tissue penetration and highly precise therapeutic delivery, ensuring superior efficacy and target engagement. Our approach integrates innovative target identification using advanced predictive models, antibody …

227 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Native and functional membrane therapeutic targets for improving Drug and Vaccine Discovery To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High …

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The only TechBio providing computationally designed antibodies through AI with biological validations associated MAbSilico is a TechBio company developing and providing AI-based solutions for antibody drug design and discovery. We help biotech and pharma companies to leverage antibody discovery risks by providing computational candidates in days which are designed and characterized in silico and validated with state-of-the-art biological technologies. While MAbSilico combines 3D modeling, interaction simulation and linear sequences analysis, the antibody drug candidates are defined through their epitope, affinity, off-target risk, cross-species reactivity and developability assessment to be ready for biological activity evaluation. Using NLP technologies we gather information …

61 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Natural Language Processing Synthetic Biology

The clear path to small molecule visualization & quantification Over the past decade, Immusmol specialized in the development of antibodies against low molecular weight compounds (<900 Daltons), eventually building a portfolio of unique primary antibodies and ELISA kits for research use. 50 + unique primary antibodies We develop monoclonal & polyclonal antibodies and staining procedures for the visualization of small molecules in cells & tissues. 80+ ELISAs cross-validated by LC-MS Our team develops highly sensitive ELISA kits to measure amino acids and their metabolites in biological samples. 600+ clients served worldwide We deliver our products worldwide through Fedex and developed …

114 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). • Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors. • Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL. • OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. • FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase …

188 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Your key partner for breakthrough antibody discovery Mabqi specializes in the discovery and development of human therapeutic antibodies. Our core technology is based on proprietary synthetic fully human libraries including pH-sensitive variants tailored for oncology applications. The company offers end-to-end discovery solutions, from antibody discovery, affinity maturation to optimization and full characterization, ensuring tailored support and delivery of high-quality and developable antibodies to meet your needs. Moreover, based on our know-how and technologies, Mabqi is committed to the discovery of therapeutic antibodies on innovative targets with off-the-shelf antibody assets available for partnered development and licensing opportunities. Antibody Discovery, Fully Human …

79 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The innovation of nano-antibodies in the service of medical diagnosis. A strategic alliance between LISM and BioCytex. NVDIAG — acronym for Nano-antibody generation using extracellular Vesicles for DIAgnostic purposes — is a joint laboratory (LabCom) born from a bilateral partnership between the Macromolecular Systems Engineering Laboratory (LISM) and the company BioCytex, both located in Marseille. NVDIAG plays a leading role in innovation in hemato-oncology, focusing on the development of camelid monoclonal antibodies (nanoantibodies) for a wide range of tests and companion diagnostic solutions. This work benefited from support from the French government under France 2030, as part of the Aix-Marseille …

85 similar entities Type: Startup Activities: deeptech healthtech biotech Technologies: Synthetic Biology

Heidelberg Pharma is a biopharmaceutical company working on a new treatment approach in oncology and developing novel drugs based on its ADC technologies for the targeted and highly effective treatment of cancer. ADCs are antibody-drug conjugates that combine the specificity of antibodies with the efficacy of toxins to fight cancer. Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells. Heidelberg Pharma uses several compounds and has built up an ADC toolbox that overcomes tumor resistance via numerous pathways and …

201 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

NUCLEIC ACID CAPTURE FOR LIQUID BIOPSY BIOCAPTIVA is an award-winning biotechnology company based in Edinburgh, dedicated to revolutionising liquid biopsy and nucleic acid (NA) extraction. Harnessing our proprietary msXTM polymer technology, we are addressing critical challenges in the liquid biopsy market, empowering breakthroughs in genetic disease detection, diagnosis, monitoring, and treatment. Our advanced extraction method ensures unparalleled cell-free NA yield and quality, driving progress in precision medicine and multi-omics research. What Sets Us Apart: Our Patented NA-Binding Polymers Our innovative, biocompatible NA-binding polymers offer unmatched benefits: Flexibility: Customisable coatings for diverse substrate formats, including bead-based systems and automated workflows. Versatility: …

128 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering therapies based on aptamer technology aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept. Biopharmaceutical, Biotechnology, Aptamers, Immunology, Stroke, and Inflammatory diseases

390 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The cloud lab for protein designers Proteins are the most advanced nanotechnology we know of. At Adaptyv Bio we’re building a next-gen protein foundry to allow you to synthesize and test any protein you design.

74 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Designing functional antibodies for the most challenging targets. Antiverse is a Welsh techbio company specialising in antibody design for challenging drug targets, such as GPCRs and ion channels. We exist to create new enabling technologies that bring new therapies to patients to change lives. Headquartered in Cardiff, UK and with offices in Boston, MA, we combine state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. Machine Learning, Antibodies, and Drug discovery

149 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Generative A.I. Synthetic Biology

Breaking Biology Free Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, including binders (nanobodies, bispecific antibodies), toxic proteins, and phage proteins.

165 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

🔬 NextGen Functional Ingredients. Protein-based microencapsulation for probiotics, bioactives and flavours. Green Nanotechnology NUCAPS@ is a consortium comprised by two Pharmaceutical companies (Laboratorios Cinfa and IDIFARMA), a Food Technological Center (CNTA) and the University of Navarra. T his consortium has developed new solutions based on the use of Food proteins (GRAS) as casein, zein or soya for the oral delivery and controlled release of drugs/actives and/or microorganisms. Nanotechnology, Encapsulation, Nanoencapsulation, Microencapsulation, Food, Nutrition, Cosmetic, Farmaceutic, Pharmaceutical, Health, Probiotics, Bioactives, Flavourings, and Biomolecules

65 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology Bio sourced materials

Our innovative technology from French research (CNRS Bordeaux) makes it possible to manufacture monodisperse polymer beads (CV<20%), very magnetic (iron oxide content >70%), calibrated from 100 to 500 nm (+/- 10 nm), offering a high specific surface area (5 to 25 m2/g). These magnetic beads are stable, sensitive and quickly separable under magnetic field. These particles are particularly well suited to be integrated into microfluidic devices. Their surface is, and can be, functionalized by the grafting of molecules of biological interest, in order to capture, isolate and separate, analyze or purify biological entities (molecules, oligonucleotides, cells, viruses) in a total …

74 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Developing Next Generation mRNA Vaccines pHion Therapeutics is a UK based biotech delivering ground-breaking nucleic acid vaccines and therapeutics. The proprietary RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo (RNA and DNA), irrespective of size, into nanoparticles. These nanoparticles are highly efficient at cellular entry with 100% release from the endosomes. When used in vaccines, the RALA platform can deliver multiple anionic molecules, such as mRNA, in a stealth-like way by evading detection. This generates both a potent antigen-specific CD8+ T-cell response that is ideal for therapeutic vaccines, and a …

128 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The native drug discovery enablers for complex targets. Let's pioneer together! Cube Biotech is a contract research organization of membrane protein scientists offering non-GMP services for many applications. We assist in protein preparation, biophysical target characterization, and structure determination by cryo-EM or assay development. Our USP is a vast synthetic copolymer portfolio, enabling more reliable membrane protein research. Copolymers offer, in contrast to detergents, a broad and native picture of your target. Discover endless customization possibilities with our Protein Services – your project, your way, as easy as building with Lego bricks! Build frameworks that are easily incorporated into your …

183 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Phico Therapeutics is a biotechnology company advancing the war on antibiotic resistance with engineered phage therapy. At Phico, we are developing a unique antibiotic technology to address one the most urgent challenges facing medicine today – how to destroy multi-drug resistant bacteria, the so-called “superbugs”. Our patented platform utilises an antibacterial protein, SASP to inactivate bacterial DNA and cause rapid destruction of target bacteria. With a number of advantages over conventional antibiotic classes, SASPjectTM could form the basis for a new generation of antibiotics to overcome antimicrobial resistance. Watch our animation to discover how our technology works: https://www.youtube.com/channel/UCjPndK0F9ufmEy9fBQFTsUg Twitter: @Phicotx …

65 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Addressing "undruggable"​ oncology targets by delivering whole antibodies inside the tumor and metastatic cells. Libera Bio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface, transmembrane or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins. << Fraud Alert for Potential Candidates >> At Libera Bio, your personal information and online safety are our top priorities. • Candidates should apply exclusively through our official webpage at https://www.liberabio.com/contact/ or rrhh@liberabio.com. • If …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Phialogics state of the art platform transforms native proteins into powerful therapeutics. Phialogics is developing a pipeline of bi-functional, bi-specific and multi-specific molecules to treat autoimmune diseases. Our unique First-in-Class immunomodulatory approach has a proof of concept in several translational in vivo models as well as in patient-derived materials ex vivo.

91 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Protein Sciences (www.proteinsciences.com) is a biotechnology company that specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals. See where Flublok® Influenza vaccine is available at www.flublok.com. We use our proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost. We have developed three main business lines that employ this technology: 1. Proprietary vaccines - we develop and produce the next generation of safer and more effective vaccines 2. GeneXpress® …

133 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Development of covalent small molecules to transform the treatment of autoimmune and inflammatory disorders ARTICA Therapeutics and its seasoned team started operatons in 2020 and was supported by pre-Seed financing from BioGeneration Ventures. Artica is dedicated to developing novel small molecule medicines for inflammatory and autoimmune indicatons. Artca is at the forefront of covalent binding technology as well as in label-free cellular-based screening approaches. The unique combinaton of these capabilities allows rapid progression of the best drug candidates that have unprecedented and superior characteristics, creating novel and highly selective therapies for patients with unmet medical need.

71 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Innovating with AI and nanotechnology to develop more effective health products in less time NanotheraTM is a startup that offers innovative solutions in R&D (Design/Nanoformulation) intended for parapharmaceutical and pharmaceutical laboratories. We combine AI and nanotechnology for more effective therapeutic solutions in less time. nanotechnology, Nutraceuticals, and Artificial Intelligence

77 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

EXIST Start-up Project Lumatix Biotech is developing a light-controlled affinity matrix for an effective and rapid isolation of antibodies. Our new chromatography technology is intended to significantly advance antibody manufacturing, particular with regard to product quality as well as economic aspects. To achieve these ambitious goals and become a superior alternative to Protein A chromatography, we combine several proprietary technologies. The key innovation here is an affinity matrix with a light-controlled binding mode. By this means, the operator can easily capture antibodies in any user-defined buffer, making acidic elution obsolete. Have a look at our website for further information and …

96 similar entities Type: Startup Activities: deeptech Technologies: Synthetic Biology

🌿 Green nanoparticles for laser-based therapy Torskal is an early clinical-stage French biotech company specializing in green nanomedicine and laser-based therapies. The company develops eco-friendly gold nanoparticles produced through sustainable synthesis technologies for applications in oncology and women’s health. Its pipeline includes three lead programs: NT1 for skin cancer, NT2 for gastrointestinal (GI) cancers, and NT3 for endometriosis, leveraging nanoparticle-mediated laser therapy approaches Nanotechnology, Nanomedicine, Biotechnology, Nanotheranostics, Nanoparticles, Gold Nanoparticles, Cancer Research, Green Nanotechnology, and laser

82 similar entities Type: Startup Activities: nanotech biotech deeptech Technologies: Synthetic Biology

Servier Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immune-oncology - Symphogen’s strategic focus is to apply our streamlined and effective antibody platform and capabilities in the discovery and early development of highly differentiated antibodies. The aim is to develop novel compounds either as combination or as stand-alone therapies for difficult to treat cancers. oncology, immune-evasive, and AXL

215 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics. AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs …

144 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Nascent’s development approach utilizes the immune system’s innate capabilities and selectivity. Nascent Biotech, Inc. (OTCMKTS:NBIO) is a public company, formed in March 2014, to continue development of Pritumumab, a human monoclonal antibody created by a number of leading scientists who have developed various monoclonal antibodies and cytokine treatments for oncology indications. Pritumumab recognizes a unique and proprietary antigen expressed on the surface of cancer cells and is being developed to treat brain and pancreatic cancers, both unmet clinical needs. NBIO’s clinical premise is that the most effective way to treat disease is to modulate (boost or suppress) the human body’s …

113 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

nanoMIPs - synthetic antibodies with robust characteristics and secure supply Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes …

58 similar entities Type: Startup Activities: manufacturing deeptech biotech Technologies: Synthetic Biology

Our specificity, your antibodies Pioneer in antibodies’ field, Agro-Bio provides you its expertise and its know-how for production, development and characterization of antibodies. For over 40 years, our team supports pharmaceutical and in vitro diagnostic industries as well as public institutions for their immunology issues. We collaborate both to offer you the most suitable and effective solution. Our goal is the success of your projects. Our services around antibody: • Bioanalysis/Biopharma: o Anti-idiotypic antibodies for positive control, PK and potency test, o Host Cell Protein issue management: specific anti-HCP antibodies, 2D Western Blot coverage analysis, specific ELISA kit, o Epitope …

84 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Covalab is a French biotechnology company specialized in antibody engineering, founded in 1995. We are expert in the design and development of antibody (polyclonal, monoclonal scFv, FAb, VHH, recombinant antibodies) using antigen or DNA immunization. In addition, we offer purified and labeling antibodies, peptide synthesis for research use, diagnostic and therapeuthic. As a producer, we supply many distributors to sale our innovative and high quality antibodies. Wide range of those products are available in our website. The service activity of CovalAb represents the top of the scientific and technical iceberg which the team at CovalAb has put together. Indeed, the …

106 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Causeway Sensors uses nanotechnology to provide better candidate selection during drug development. The company spun-out after years of high-impact research at Queen's University Belfast. Our unique nanochip platform brings real-time, label-free kinetic analysis to areas of biotherapeutic production where such data cannot currently be collected. More data at critical points of production helps pharma companies ensure that only the best drug candidates progress to clinical trials. The platform can be incorporated into a multitude of form factors, ranging from a high-throughput screening instrument to an in-line cell culture monitoring tool. Biosensing, Protein - Protein Interactions, Binding Kinetics, Biotechnology, Biotherapeutics, Antibody …

422 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics Synthetic Biology

At FairJourney Bio, we specialize in cutting-edge antibody discovery and development, offering end-to-end solutions that fast-track your research. With over a decade of expertise, our innovative technologies and seasoned team have successfully advanced 19 antibodies to clinical stages. Our adaptable partnership model empowers projects of any scale, fostering collaboration and breakthrough innovation. Whether you're in early-stage research or development, we deliver tailored, high-quality antibodies designed to meet your specific needs. Join us in revolutionizing therapeutic discovery and making lasting impacts on global healthcare. Monoclonal antibodies, Antibody humanization, Antibody production, Antibody affinity maturation, Phage display libraries, Mammalian Display, Naïve Libraries, VHH …

193 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.

177 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

An immunotherapy company focused on infectious diseases Centauri Therapeutics Limited is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity"​ in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a …

78 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Antibody Magic Oblique Therapeutics AB (publ.) is a Swedish biotech company developing innovative new medicines for severe diseases with a large unmet medical need with an internal pipeline focusing on pain. The company uses Abiprot®, a proprietary, next-generation antibody platform to identify accessible epitopes for antibody development. biotech, antibody, drug development, and pain

Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology